Jennison Associates Reduces $61M in Edwards Lifesciences Corporation ($EW)
Key Points
- Jennison Associates changed its Edwards Lifesciences Corporation ($EW) stake by 5.2% last quarter, cutting to 13,066,274 shares worth $1.12 billion.
- Wall Street's consensus rating on $EW is Buy and an average price target of $96.92.
- $EW last traded around $85.76.
Jennison Associates trimmed its position in Edwards Lifesciences Corporation ($EW) by 5.2% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,066,274 shares of Edwards Lifesciences Corporation after selling 714,241 shares during the quarter. Jennison Associates's holdings in Edwards Lifesciences Corporation were worth $1.12 billion as of its most recent filing.
Edwards Lifesciences Corporation ($EW) Stock
Edwards Lifesciences Corporation Earnings
Analysts Set New Price Targets
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.